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Abstract 
Background 
There is a pressing need to identify prognostic and predictive biomarkers for 
prostate cancer to aid treatment decisions in both early and advanced disease settings. 
Syndecan-1, a heparan sulfate proteoglycan, has been previously identified as a potential 
prognostic biomarker by multiple studies at the tissue and serum level. However, other 
studies have questioned its utility.  
Methods 
Anti-Syndecan-1 immunohistochemistry was carried out on 157 prostate tissue 
samples (including cancerous, adjacent normal tissue and non-diseased prostate) from 
three independent cohorts of patients. A population of Syndecan-1 positive stromal cells 
was identified and the number and morphological parameters of these cells quantified. The 
identity of the Syndecan-1-positive stromal cells was assessed by multiplex 
immunofluorescence using a range of common cell lineage markers. Finally, the burden of 
Syndecan-1 positive stromal cells was tested for association with clinical parameters. 
Results 
We identified a previously unreported cell type which is marked by Syndecan-1 
expression and is found in the stroma of prostate tumors and adjacent normal tissue but 
not in non-diseased prostate. We call these cells Prostate Cancer Syndecan-1 Positive (PCSP) 
cells. Immunofluorescence analysis revealed that the PCSP cell population did not co-stain 
with markers of common prostate epithelial, stromal or immune cell populations. However, 
morphological analysis revealed that PCSP cells are often elongated and displayed 
prominent lamellipodia, suggesting they are an unidentified migratory cell population. 
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Analysis of clinical parameters showed that PCSP cells were found with a frequency of 20-
35% of all tumors evaluated, but were not present in non-diseased normal tissue. 
Interestingly, a subset of primary Gleason 5 prostate tumors had a high burden of PCSP cells.  
Conclusions 
The current study identifies PCSP cells as a novel, potentially migratory cell type, 
which is marked by Syndecan-1 expression and is found in the stroma of prostate 
carcinomas, adjacent normal tissue, but not in non-diseased prostate. A subset of poor 
prognosis high Gleason grade 5 tumors had a particularly high PCSP cell burden, suggesting 
an association between this unidentified cell type and tumor aggressiveness.  
 
Key Words: 
Syndecan-1; SDC1; CD138; prostate cancer; immunohistochemistry; stromal cells 
Introduction 
Prostate cancer accounts for almost a quarter of all cancers diagnosed in European 
men, with a large increase in incidence over the past 20 years due to increased detection 
through PSA testing. Radical treatments such as surgery or radiotherapy have considerable 
morbidity and there is increasing enthusiasm for a period of active surveillance in patients 
with low volume, low-intermediate risk disease. However, we currently do not have any 
useful biomarkers beyond Gleason grade to help inform which patients would be better 
suited to surveillance. Likewise, in the case of metastatic prostate cancer, there is a lack of 
useful biomarkers to help direct the choice and sequencing of drug treatments such as 
chemotherapy, abiraterone and enzalutamide. One potential biomarker that has been 
investigated is the heparan sulfate proteoglycan Syndecan-1. 
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The expression of Syndecan-1 has been linked to prognosis and treatment response 
in a large range of cancer types, including hematolymphoid malignancies and solid tumors 
(1-6), but in prostate cancer the role of Syndecan-1 in prognosis is controversial. It is 
expressed in the basal epithelial layer of normal prostate glands, and this expression is often 
lost in prostate carcinoma cells (7-12). However, there are reports that hormone-refractory 
tumors (9) and tumors treated with neo-adjuvant hormone therapy (8) have increased 
Syndecan-1 expression, suggesting a relationship between expression and androgen 
independence. There is also evidence that expression of Syndecan-1 is associated with high 
Gleason grade disease and/or early disease recurrence in prostate cancer patients (7-11). 
Interestingly, an alteration in protein localization, from membranous to cytoplasmic, was 
found to be associated with a more rapid biochemical recurrence (13). This indicates that 
alterations in Syndecan-1 expression and localization could be prognostically important and 
change throughout the course of the disease. Conversely, others have found that Syndecan-
1 expression is not associated with recurrence-free survival (9,14) or Gleason grade in 
prostate carcinoma (9), and even concluded that lower levels of Syndecan-1 expression 
were associated with a high Gleason grade (1). Therefore, the potential utility of Syndecan-1 
as a biomarker for prostate cancer is far from clear. 
The function that Syndecan-1 plays in normal and cancerous tissues is also 
complicated. Syndecan-1 protein has been linked to a wide range of cellular processes, 
acting as an extracellular matrix receptor as well as participating in growth factor binding 
through the heparan sulfate chains on its extracellular domain (Reviewed in (1)). The 
extracellular domains of Syndecan-1 can also be shed through cleavage by matrix 
metalloproteinases, creating a soluble form which may have pro-angiogenic roles in tumors, 
for example in myeloma (1), and this shed ectodomain in itself may possess prognostic 
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utility (12). There is also evidence that Syndecan-1 signaling is involved in maintaining the 
tumor-initiating cell/cancer stem cell population in breast carcinoma (15,16) and prostate 
carcinoma (17) and can regulate the expression of several miRNAs that suppress expression 
of stem cell markers such as SOX-2, OCT4 and Nanog (11). Suppression of Syndecan-1 gene 
expression also reduces amplification of the putative tumor-initiating cell population 
following treatment with docetaxel (17), suggesting that it could exert effects of relevance 
to prostate cancer patients undergoing therapy. Taken together, there is accumulating 
evidence that Syndecan-1 is an important multifunctional molecule that shows altered 
expression in prostate cancer, but its potential role as a biomarker for prostate cancer 
remains controversial. 
Given the interesting functional roles played by Syndecan-1 and the conflicting 
evidence surrounding its possible utility as a biomarker, we investigated Syndecan-1 
expression in three independent cohorts of prostate carcinoma samples. We identified a 
previously unreported cell type which is marked by Syndecan-1 expression and is found 
scattered in the stroma of a third of prostate carcinomas and in their adjacent normal tissue, 
but not in normal tissue. We call these cells Prostate Cancer Syndecan-1 Positive (PCSP) cells. 
Common markers for immune cells, cancer epithelial cells and stromal cells failed to identify 
the cell type, but further analysis showed that PCSP cells are elongated and have prominent 
lamellipodia, suggesting they are a migratory cell type. Finally, comparison of the 
relationship between PCSP cell burden and clinical features showed that a subset of poor 
prognosis high grade tumors have a particularly high burden of these cells. 
Materials and Methods 
Patients  
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The study was conducted following local ethics approval (REC reference: 
13/WS/0153; IRAS project ID: 112241). Data was obtained from three separate cohorts of 
patients with associated formalin-fixed, paraffin-embedded (FFPE) prostate material 
available. The total number of cancer cases in the study was 157. The Bath cohort was used 
for analysis of cell types by co-staining, and consisted of 6 prostate cancer patients with 
confirmed Syndecan-1+ stromal cells as assessed by anti-Syndecan-1 IHC. In addition, one 
block of adjacent normal prostate tissue was used as a positive control for Syndecan-1 
staining. These samples were obtained retrospectively from patients treated for prostate 
cancer at the Royal United Hospital, Bath, United Kingdom, between 1997 and 2008. The 
other two cohorts, consisting of 151 cancer cases in total, were used for anti-Syndecan-1 
immunohistochemistry and were obtained from US Biomax (Rockville, MD, USA). The first 
cohort (PR1921) consisted of 80 cases of prostate adenocarcinoma with 8 cases of adjacent 
normal prostate tissue and 8 cases of histologically normal prostate tissue, with duplicate 
1mm diameter cores per cancer case for a total of 196 cores. The second cohort (PR803b) 
consisted of 71 cases of prostate adenocarcinoma, 2 cases of prostate leiomyosarcoma, 1 
case of benign prostate hyperplasia and 6 cores of histologically normal prostate, with a 
single 1.5mm core per case. Each cohort was contained in a single tissue microarray block. A 
summary of the patient characteristics of tissue microarray cohorts is given in Table I. 
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Immunohistochemistry 
For immunohistochemistry, 5um thick sections of FFPE prostate tissue or tissue 
microarrays were used. Cohort 1 and cohort 2 were stained in separate experiments. Briefly, 
sections were baked for 30 minutes at 60°C before being deparaffinized in Histoclear 
(National Diagnostics, Hessle, UK) and rehydrated through a graded ethanol series of 
decreasing ethanol concentration. Sections were washed with PBS-tween (0.05%), 
permeablized with 0.5% triton X-100 in PBS, subjected to heat-induced epitope retrieval in 
10mM Citrate buffer with 0.05% Tween 20 at pH 6.0 for 30 minutes at 90°C, and allowed to 
cool to room temperature for 20 minutes. Endogenous peroxidases were blocked with Dako 
Peroxidase Block, following the manufacturer’s instructions. After blocking for 30 minutes in 
10% normal goat serum and 0.5% BSA in PBS, samples were incubated with primary 
antibodies (Table II) diluted in Dako Antibody Diluent (Dako, Ely, UK) overnight at 4°C. The 
next day, samples were washed and bound antibodies were visualized using the EnVision+ 
Kit (K400611-2 and K401011-2, Dako, Ely, UK) following the manufacturer’s instructions with 
DAB exposure for 5 minutes. Nuclei were counterstained with Gill’s Hematoxylin (H-
3401,Vector Laboratories, Peterborough, UK) and mounted in DPX (Sigma-Aldrich, Dorset, 
UK). Stained tissues were viewed under a Nikon Eclipse E800 microscope with brightfield 
illumination and photographed with a Nikon Digital Sight DS-U1 CCD Digital Camera. 
Negative controls were IHC-stained sections of prostate carcinoma tissue with no primary 
antibody added, and showed no positive staining (data not shown). 
Anti-Syndecan-1 Antibodies 
Three distinct Syndecan-1 antibodies were used (Table II). The three antibodies were 
selected as they have been previously shown to successfully detect Syndecan-1. The first 
mouse monoclonal anti-Syndecan-1 antibody, (Novus Biologicals: clone B-A38: Cat NB100-
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64980), later referred to as mo anti-SDC1 #1, has been shown to robustly mark a CD45-
expressing plasma cell population by flow cytometry (18), a cell population which expresses 
Syndecan-1 (19). The second mouse monoclonal (Dako; clone MI15: Cat M7228) has been 
shown to recognize the ectodomain of Syndecan-1 (20). Antibody blocking experiments 
show that it partially shares the epitope of B-B4, which occurs at residues 90-93 of the 
mature Syndecan-1 protein (21). The rabbit polyclonal anti-Syndecan-1 antibody (Santa Cruz 
Biotechnology: SC-5632) was generated by immunization with amino acids 82-256 of human 
Syndecan-1, corresponding to the human Syndecan-1 ectodomain, and successfully 
immunoprecipitated the ectodomain (22), showing that the antibody can detect the cleaved 
ectodomain of the protein. The rabbit antibody is also known to detect Syndecan-1 positive 
plasma cell populations by immunohistochemistry (23).  
Scoring 
For assessment of IHC staining on the two tissue microarrays, whole cores were 
examined under a 10x objective to determine the presence of Syndecan-1 staining in 
prostate epithelium. Cores were scored as either positi e or negative for Syndecan-1 
epithelial reactivity based on the observed staining patterns across the core.  
For quantification of PCSP cell burden, fields of view of all PCSP cells in every core 
were manually acquired under a 20x objective. Counting and measuring of the resulting 
images was performed using ImageJ v2.0.0. Each PCSP cell was identified manually and the 
following size and shape descriptors were measured: area, circularity, aspect ratio, 
roundness and solidity. Mean values were taken for each measure within each cohort as a 
whole, and for each patient. 
Data Analysis 
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To analyze the distribution of Syndecan-1+ cell burden amongst different patient 
groups in both TMA cohorts, we classified patients into Syndecan-1 stromal cell positive and 
negative categories based on whether Syndecan-1+ stromal cells were present or absent in 
the core. In the case of PR1921, where duplicate cores were scored, patients were classified 
as positive if at least one core contained Syndecan-1+ stromal cells. The distributions of 
Syndecan-1+ and Syndecan-1- patients amongst different levels of clinical variables were 
tested with the chi-squared test performed in R version 3.2.0 with default parameters. 
Clinical variables assessed were: age; stage; Gleason grade; T, N and M stages; Presence of 
Syndecan-1 staining in the glandular compartment was also scored as positive or negative, 
and tested for association as with clinical variables. A p-value of less than 0.05 was 
considered statistically significant. Graphs were generated in R version 3.2.0. 
Immunofluorescence 
For immunofluorescence co-staining of Syndecan-1 with other markers, double-
labelling was performed on FFPE prostatectomies, biopsies and TURP chips with confirmed 
PCSP cells as determined by prior IHC experiments. 5um thick sections were deparaffinized, 
rehydrated, permeablized and subjected to antigen retrieval as for immunohistochemistry. 
Omitting the peroxidase blocking step, samples were blocked with the same blocking buffer 
and incubated with a mixture of two primary antibodies raised in different species, 
overnight at 4°C, as before. Cell type markers and either the rabbit polyclonal or the first 
mouse monoclonal (mo anti-SDC1 #1) anti-Syndecan-1 antibodies were chosen, depending 
on the host in which the marker antibody was raised. The antibodies used in this study are 
described in Table II. The following day, samples were washed and incubated in a secondary 
antibody cocktail containing goat anti-mouse alexafluor-488 (A-11001, Invitrogen) and goat 
anti-rabbit alexafluor-568 (A-11008, Invitrogen), each at 1:200 dilutions in Dako Antibody 
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Diluent, for 30 minutes. The specimens were then incubated with a solution of 0.1% (w/v) 
Sudan Black B (199664, Sigma-Aldrich, Dorset, UK) in 70% ethanol for 10 minutes to quench 
endogenous tissue autofluorescence, as adapted from (24). Mounting was achieved in 
Mowiol-4-88 (Millipore) with 600nM DAPI (D9542, Sigma-Aldrich) added. Slides were 
allowed to set overnight in the dark at room temperature before imaging on a ZEISS LSM510 
META confocal laser scanning microscope. Negative controls were IF-stained sections of 
prostate carcinoma tissue with no primary antibody added, and never showed positive 
staining (data not shown). 
To score Syndecan-1+ stromal cells for their colocalization with test markers, images 
from each experimental run were pooled, and each Syndecan-1+ cell was manually scored 
for positivity of the co-stained marker. The percentage of marker-positive cells was 
calculated as the percentage of Syndecan-1+/Marker+ cells relative to the total number of 
Syndecan-1+ cells in an experimental run. 
Results 
A population of Syndecan-1 positive cells was found in the stromal compartment 
of a subset of prostate tumors 
 Syndecan-1 expression was analyzed using IHC and IF in samples from three 
independent cohorts of patients (See Materials and Methods).  Expression was found in the 
cell membrane and cytoplasm of the prostate epithelium basal, but not luminal, cell layer in 
histologically normal tissue (Figure 1A, Left Panel). In prostate carcinoma tissues there was 
either a loss of epithelial staining or a widespread expression of the proteoglycan 
throughout the cytoplasm and/or cell membranes of prostate tumor epithelium (Figure 1A, 
Middle and right Panel). These patterns are consistent with previous studies 
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(3,7,10,12,13,25) and provide positive (basal prostate epithelium) and negative (luminal 
prostate epithelium) control cells for the IHC staining. Interestingly, in addition to these 
staining patterns, a population of scattered Syndecan-1 positive cells was found in the 
stroma in a subset of cancer cases (Figure 1A). These scattered cells were present in a 
subset of tumor samples from each of the three cohorts, either proximal or distal to an 
epithelial region. A range of examples, including samples from all three cohorts, are shown 
in Figure 1B. The staining was found to be localized to the membranes and/or cytoplasmic 
regions of the Syndecan-1 positive cells, and the cells often appeared in close proximity to 
areas of apparent inflammation, characterized by the presence of stromal cells with round, 
compact and hyperchromatic properties suggestive of an immune cell phenotype (Figure 1B, 
Adjacent to stained cells in the inserts and near arrowheads. The bottom left panel insert 
shows a clear example). 
To confirm that the staining was due to the presence of Syndecan-1, and not cross 
reactivity from the mouse monoclonal antibody (Clone B-A38), two additional anti-
Syndecan-1 antibodies were used. A rabbit polyclonal antibody and a second mouse 
monoclonal (Clone MI15) were used. Staining of sequential sections of normal prostate and 
tonsil by IHC showed that all three antibodies stained the same basal, but not luminal, 
epithelial cell populations (Figure 2A and B). This specific pattern of expression provides 
positive and negative controls for the three antibodies and, combined with validation of the 
antibodies carried out in previous publications (see materials and methods), argues that 
they can be used to reliably identify Syndecan-1 positive cells. The two additional anti-
Syndecan-1 antibodies (rabbit polyclonal and second mouse monoclonal), like the original 
mouse monoclonal antibody, also detected scattered Syndecan-1 positive cells in the 
stroma of prostate tumors (Figure 2C).  
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 A final experiment to validate the anti-syndecan-1 antibodies was carried out using 
IF staining of normal and prostate carcinoma tissues. This made it possible to establish if the 
different antibodies were staining the same populations at a single cell level. IF staining 
using the mouse monoclonal #1 and the rabbit polyclonal antibody showed colocalisation of 
Syndecan-1 staining in individual basal, but not luminal, epithelial cells of adjacent normal 
prostate (Figure 3, upper panels).  Importantly, colocalization of Syndecan-1 staining was 
also seen in the scattered tumor stromal cells (Figure 3, lower panels arrows and inserts), 
confirming that the two antibodies stain the same population of scattered stromal cells.  
In summary, the use of three independent antibodies showed that a subset of 
prostate cancer samples, from three cohorts of patients, contained a population of 
scattered Synecan-1 positive cells, which to our knowledge have not been previously 
described. We call these cells Prostate Cancer Syndecan-1 Positive (PCSP) cells. 
 
PCSP cells do not express common epithelial, mesenchymal or immune cell 
markers 
To begin to characterize the PCSP cell population, we used double-IF labelling with 
Syndecan-1 and a range of markers commonly used to distinguish key cell types found in 
prostate tumor samples from the Bath cohort. Given that Syndecan-1 is expressed in normal 
and neoplastic plasma cells (19), we began by assessing the expression of hematolymphoid 
lineage markers in PCSP cells. Fluorescent co-stains with Syndecan-1 and a panel of 
antibodies raised against immune cell lineage markers: CD45, which is expressed in the 
majority of hematolymphoid lineages with the exception of erythrocytes and some 
macrophages, and known to be expressed in Syndecan-1+ bone marrow plasma cells (18); 
CD19, which is expressed on immature and memory B-cells (26); CD27, which is expressed in 
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plasma cells, memory B-cells (26) and T-cells (27); and CD73, an ecto-5’-nucleotidase 
expressed on subsets of T and B lymphocytes (28), as well mesenchymal stem cells which 
have been previously shown to infiltrate prostate tumors (29). To confirm the antibodies for  
these markers were performing as expected they were used to stain positive control tonsil 
or placenta tissues (Supplementary Figure 1). In each case the staining was as expected.  
In prostate tumors, the majority of PCSP cells did not co-stain for any of the three 
immune cell markers or the mesenchymal stem cell marker (Figure 4A+B). Interestingly, 
despite the lack of colocalization, PCSP cells were often found in close proximity to CD45-
positive immune cells (Figure 4A: See inserts in the top panel). This was consistent with IHC 
data showing that Syndecan-1 positive cells were found in close proximity to cells whose 
nuclear morphology was consistent with an immune cell phenotype (Figure 1B, Adjacent to 
stained cells in the inserts and near arrowheads. The bottom left panel insert shows a clear 
example). 
Given that Syndecan-1 is expressed in the basal cells of normal prostate, another 
possible origin for the PCSP population was prostate epithelial cells, so co-staining was 
carried out for Syndecan-1 and three markers of epithelial cell fate: pan-Cytokeratin, which 
stains multiple human cytokeratins expressed in epithelial tissues including both basal and 
luminal prostate epithelial cell layers (Figure 5A); E-Cadherin, which is normally expressed 
throughout the normal prostate epithelium and in most prostate tumors (30); and Prostate-
Specific Antigen (PSA), a secretory marker of luminal prostate epithelium, also expressed in 
prostate tumors. Quantification of the IF images showed none of these markers had 
significant co-staining with Syndecan-1 in PCSP cells (Figure 5B). There was also no apparent 
overlap in the IHC staining of the stromal cells in consecutive tissue sections for Syndecan-1 
and the basal cell markers p63 and Cytokeratin-5 (Figure 5C, lower panels). This was clearly 
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distinct from the situation in the basal cells of adjacent normal tissue, where the markers do 
overlap with Syndecan-1 staining (Figure 5C, upper panels). Thus, despite the overlap in 
normal epithelium, PCSP cells did not have staining patterns consistent with them being a 
recognized prostate epithelial cell population, whether basal or luminal in origin.  
To examine if the PCSP cells were stromal, mesenchymal or had undergone an 
epithelial-mesenchymal transition and lost expression of epithelial markers, a panel of 
stains for mesenchymal and stromal cell types was examined. The mesenchymal cell 
markers Vimentin and N-Cadherin did not show significant co-staining with PCSP cells 
(Figure 6A+B). Finally, the neural marker S100 and the endothelial marker CD31 were 
examined (Figure 6A), neither of which showed significant overlap (Figure 6B). Therefore, 
the marker analysis carried out did not allow the allocation of PCSP cells to an established 
cell population, and they remained an undefined cell type. 
 
 PCSP cells are elongated and have prominent lamellipodia-like structures 
In order to characterize this unidentified cell type further, the shape of PCSP stromal 
cells was analyzed using IHC stained tissue microarrays from two independent cohorts of 
prostate cancer patients. The circularity and aspect ratios of the PCSP cells were quantified 
and on average PCSP cells were found to be elongated rather than rounded in shape (Table 
III). When morphological data from individual cells of both TMA cohorts were pooled, a tail 
of elongated cells with high aspect ratio and low circularity was apparent (Figure 7A).  To 
further characterize this subpopulation of elongated cells, confocal laser scanning 
microscopy was used to carry out high resolution three dimensional imaging of the PCSP 
cells. They were found to have striking lamellipodia-like protrusions (Figure 7B, arrows) and 
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polarized cell bodies and nuclei (Figure 7B, arrowheads). The elongated shape and 
prominent protrusions support the hypothesis that PCSP cells may be a migratory cell type. 
 
 A subset of Gleason grade 5 tumors had a particularly high PCSP cell burden 
Using the clinical metadata available for both prostate tissue microarray cohorts, we 
wished to determine if there was a relationship between PCSP cell burden and 
clinicopathological features. These included age, Gleason grade and TNM stages. In the first 
cohort, cores of histologically normal tissue adjacent to prostate cancer were also included, 
as well as non-diseased no mal prostate control cores. Patient characteristics for both 
cohorts are summarized in Table I, and have similar patient distributions for the clinical 
variables. 
 PCSP cells were found in 28 of 80 cases (35%) of patients with prostate cancer in 
cohort 1, but they were not observed in any of the 8 control cases of non-diseased patient 
tissue (Figure 8A). PCSP cells were found in 4 of 8 cases of normal patient tissue that was 
adjacent to carcinoma (Figure 8A). In cohort 2, PCSP cells were found in 15 of 71 prostate 
cancer cases (21.1%). In both cohorts, a subset of Gleason grade five tumors had a 
particularly high burden of PCSP cells (Figure 8B+C). Among cohort 2, but not cohort 1, there 
was also a statistically significant association between PCSP cell burden and higher primary 
Gleason grade (p<0.05). In summary, analysis of PCSPs in the tissue microarrays showed 
that PCSP cells were not observed in normal prostate tissue, but were found in adjacent 
normal and in roughly 1/3 of prostate carcinoma tissues, with a subset of higher grade 
tumors having a particularly high burden.  
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Discussion 
This study identifies PCSP cells as a previously unreported Syndecan-1-positive cell 
population found in the stroma of prostate adenocarcinoma, in adjacent normal tissue, but 
not in non-diseased prostate. These PCSP cells do not express lineage markers of common 
epithelial, stromal or immune cell lineages, but do display elongated morphologies with 
lamellipodia-like structures consistent with a migrating cell type. PCSP cells appear in high 
burdens in a subset of primary Gleason grade 5 poor prognosis tumors. 
The existence of PCSP cells was confirmed using three separate antibodies 
recognizing Syndecan-1; in both immunohistochemistry and immunofluorescence, using 
samples from three different patient cohorts. However, several previous studies have 
specifically reported the absence of stromal Syndecan-1 staining in prostate tumors 
(7,10,12). It is possible that the focal nature of this cell type – and their presence only in a 
subset of tumors - has led to them being previously overlooked.  
Immune cells are commonly found in prostate tumors and Syndecan-1 is a marker of 
plasma cell differentiation, being expressed at the later stages of the transition from 
plasmablast into a mature plasma cell (31). However, we were unable to identify an immune 
cell marker profile in PCSP cells. The fact that plasma cells tend to express both Syndecan-1 
and the pan-leukocyte marker CD45 (18), whilst PCSP cells are CD45-, would suggest that 
PCSP cells are either an atypical plasma cell or a non-plasma cell population. Tumor-
associated macrophages - a component commonly associated with inflammation in tumors 
– also express CD45, being a leukocyte population, and that makes it unlikely that PCSP cells 
represent a subset of that population. However, given the enormous diversity in the 
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immune cell repertoire, it is still possible that PCSP cells represent an immune cell 
population. 
Co-staining with epithelial markers again failed to mark a significant portion of the 
PCSP cell population, despite the overlap seen in adjacent normal epithelium. There remains 
the possibility that PCSP cells could have undergone dedifferentiation, as they do not 
possess an epithelial identity consistent with tumor cells. Epithelial-Mesenchymal Transition 
(EMT) is an unlikely explanation for this observation, as PCSP cells also lacked mesenchymal 
markers such as Vimentin and N-Cadherin (Figure 5A+B). Another possibility for the lack of 
differentiation markers is a stem-like status, either derived from a resident prostate cell 
population or from a mobilized stem cell niche such as Mesenchymal Stem Cells (32) or 
cancer stem cells, although co-staining with a Mesenchymal Stem Cell marker (CD73) did 
not show any colocalisation with PCSP cells. There is evidence that Syndecan-1 signaling is 
involved in maintaining the tumor-initiating cell/cancer stem cell population in the prostate 
carcinoma cell line PC-3, where its expression marks a population of CD133+/CD44+ stem-
like holoclones (17), so a migratory dedifferentiated/stem like epithelial cell identity 
remains a possibility. It is also possible that Syndecan-1 might stain more than one 
population of cells in the stroma that overlap with different markers. We feel this is a less 
likely than a single population of PCSP cells, but a key question for future work is to identify 
the markers expressed by these cells to establish their identity and whether they represent 
more than one population of cells.  
Analysis of PCSP morphology suggests a migratory cell type, something that is 
supported by the finding that histologically normal tissue adjacent to a carcinoma can 
harbor PCSP cells. A migratory PCSP cell population could be either recruited from other 
tissues, consistent with an immune cell type; a hypothesis which is supported by the close 
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proximity of other immune cells to the PCSP cells. However, PCSP cells might also be 
migrating out from the prostate tumor and recruiting or being detected by immune cells, 
which would be more supportive of a dedifferentiated/stem like epithelial population.  
In addition to their characterization, it is important to determine the clinical 
relevance of PCSP cells. We observed that there is a trend towards increased burden in the 
primary Gleason grade 5 tumors, suggesting that PCSP burden might be related to outcome 
given that assignment of primary Gleason grade 5 is a poor prognostic factor. While cohort 2 
showed a significant association between primary Gleason grade and the presence of a 
PCSP cell burden (p<0.05), cohort 1 did not reach significance (p=0.706). This could be due 
to differences in sampling strategy between the two cohorts because of different core 
numbers and diameters, with cohort 1 having duplicate 1mm cores and cohort 2 having 
single 1.5mm cores. This could lead to differences in successful detection of Syndecan-1+ 
cells in tumors given their scattered nature. Further investigation is warranted to determine 
the relationship between PCSP burden and grade, and prognostic utility of PCSP cells in 
prostate carcinoma, as well as any potential for predicting which cancers may respond 
better to upfront systemic cytotoxic or hormone treatments, and which may benefit from 
active surveillance. 
Conclusions 
This report is, we believe, the first to identify PCSP cells, an apparently migratory 
Syndecan-1+ cell population found in the stroma of prostate tumors and adjacent normal 
tissue, but not in non-diseased prostate. In addition, we demonstrate an increased burden 
of this cell type in primary poor prognosis Gleason pattern 5 tumors. These findings provide 
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a foundation for further characterization of PCSP cells, their clinical relevance and their roles 
in prostate tumors and the adjacent normal tissue. 
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Figure Legends 
Figure 1.  Scattered Syndecan-1 positive cells are found in the stroma of prostate 
carcinoma tissue. (A) Expression of Syndecan-1 in adjacent normal and prostate 
adenocarcinoma tissue. Syndecan-1 is expressed in the basal cells of adjacent normal tissue. 
In prostate carcinoma Syncecan-1 expression is lost or found to be broadly expressed in the 
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epithelium. In addition, in a subset of prostate cancer cases Syndecan-1 positive cells were 
found scattered in the stroma (shown in the insets and by arrows), but not in adjacent 
normal prostate tissue. We call these cells Prostate Cancer Syndecan-1 Positive (PCSP) cells 
and they could be found in the contexts of both epithelial Syndecan-1 alterations in tumors, 
including expression across all epithelial cells, and where Syndecan-1 expression is lost in 
the epithelium. (B) Examples of PCSP cells detected by anti-Syndecan-1 IHC. PCSP cells were 
located in the stroma and tend to appear near regions that appear to contain immune cells 
with small, round, hyperchromatic nuclei. Images are from 3 Independent patient cohorts. 
Nuclei are counterstained with hematoxylin (blue) in IHC, or with DAPI (blue) in IF. IHC scale 
bars – 100um; IF scale bars – 50um. SDC1 – Syndecan-1. 
Figure 2. Three distinct anti-Syndecan-1 antibodies show the expected patterns of 
Syndecan-1 expression in control prostate and tonsil tissue, and stain scattered stromal 
PCSP cells. (A) Staining of adjacent tissue sections of a representative adjacent normal 
prostate and tonsil positive controls with two different mouse monoclonal antibodies 
recognizing Syndecan-1. Both antibodies stained basal cells in adjacent normal prostate 
epithelium and epithelium in tonsil as expected. (B) Staining of adjacent tissue sections of 
representative adjacent normal prostate and tonsil positive controls with a mouse 
monoclonal and rabbit polyclonal antibodies that both recognize Syndecan-1. These 
antibodies also stained basal cells in adjacent normal prostate epithelium and epithelium in 
tonsil as expected. (C) Three anti-Syndecan-1 antibodies recognise similar stromally-located 
PCSP cells in both prostate tumors and in adjacent normal prostate tissue. Example cells are 
highlighted in the magnified insets and with the arrows. Nuclei are counterstained with 
hematoxylin (blue) for IHC. Scale bars – 100um with inserts at 3x zoom; SDC1 – Syndecan-1; 
mo – mouse; rb – rabbit. 
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Figure 3. Staining from two anti-Syndecan-1 antibodies overlap in individual  
prostate epithelial cells and in the PCSP cells seen in the stroma of prostate tumors. Mouse 
monoclonal anti-Syndecan-1 antibody #1 and the rabbit anti-Syndecan-1 antibodies stained 
the same cell population following IF staining of prostate tissue. Overlap was seen in the 
basal cells of adjacent normal (Upper panels: See inserts) and in the PCSP cells found in the 
stroma of tumor tissues (Lower panels: See arrows and inserts). Nuclei were counterstained 
with DAPI (blue) in IF. Scale bars – 50um. SDC1 – Syndecan-1; mo – mouse; rb – rabbit. 
Figure 4. PCSP cells do not express common markers of immune cell lineages. FFPE 
sections of prostate tumor tissue were stained for Syndecan-1 (green) and immune cell 
markers (red). Nuclei were counterstained with DAPI (blue). (A) PCSP cells (inset) do not 
express the hematopoietic lineage marker CD45, the B-cell marker CD19, the plasma cell 
marker CD27 or the lymphocyte and mesenchymal stem cell marker CD73. (B) 
Quantification of the percentage overlap of Syndecan-1+ cells with the marker stains. 
Counts of PCSP cells were pooled from a minimum of 3 different patient samples, with a 
minimum of 200 cells counted in total per marker over at least 5 fields of view, with the 
exception of CD73 where 58 PCSP cells were counted. Scale bars – 50um. Insets: individual 
PCSP cells displayed at 3x zoom. SDC1 – Syndecan-1. 
Figure 5. PCSP cells do not express markers of epithelial and secretory prostate cells. 
FFPE sections of prostate tumor tissue were stained for Syndecan-1 (green) and epithelial 
markers (red). Nuclei were counterstained with DAPI (blue). (A) PCSP cells (inset) do not 
express the epithelial cell markers pan-Cytokeratin or E-Cadherin. Similarly, the secretory 
epithelial marker PSA was not expressed in PCSP cells. (B) Quantification of the percentage 
overlap of PCSP cells with marker stains. Counts of PCSP cells were pooled from a minimum 
of 3 different patient samples. A minimum of 200 cells were counted in total per marker 
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over at least 5 fields of view, with the exception of E-Cadherin where 176 cells were 
counted. Insets: individual PCSP cells displayed at 3x zoom. (C) Sequential sections of 
adjacent normal prostate and prostate tumors were stained for Syndecan-1 and the basal 
cell markers p63 and CK5, showing no colocalization in PCSP cells of tumor cases, despite 
the overlap seen in the basal epithelial cells of adjacent normal tissue. Insets and arrows 
show representative PCSP cells. Scale bars – 50um. SDC1 – Syndecan-1.  
Figure 6. PCSP cells do not express common markers consistent with a mesenchymal, 
stromal, neural or endothelial cell identity. FFPE sections of prostate tumor tissue were 
stained for Syndecan-1 (green) and mesenchymal/stromal cell type markers (red), and 
nuclei were counterstained with DAPI (blue). (A) Mesenchymal cell type markers Vimentin, 
N-Cadherin, nerve marker S100 and endothelial cell marker CD31. (B) Quantification of the 
percentage overlap of PCSP cells with marker stains. Counts of PCSP cells were pooled from 
a minimum of 3 different patient samples. A minimum of 200 cells were counted in total per 
marker over at least 5 fields of view, with the exception of Vimentin, N-Cadherin and S100, 
where 69, 197 and 29 cells were counted respectively. Insets: individual PCSP stromal cells 
displayed at 3x zoom. Scale bars – 50um. SDC1 – Syndecan-1. 
 Figure 7. PCSP cells are elongated and have prominent lamellipodia-like structures. 
(A) Pooled single cell measurement data of PCSP cells from both tissue microarray cohorts. 
A continuum between a more rounded cell morphology (circularity and aspect ratio close to 
1) and a tail of cells assuming a more elongated cell shape with lower circularity and higher 
aspect ratio was observed. (B) Sequential slices through a z-stack of images of PCSP cells in a 
prostate tumor tissue section. PCSP cells had an elongated cell morphology, with polarized 
nuclei and lamellipodia-like protrusions. Optical sections are 1um apart. Blue: DAPI; Green: 
Syndecan-1. Scale bar: 10um. SDC1 – Syndecan-1. 
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Figure 8. Distribution of PCSP cells in normal, adjacent normal and prostate 
carcinoma. (A) Plots of PCSP cell burden in cohort 1. PCSP cells were detected in 0/8 normal 
samples, 4/8 adjacent normal (NAT) samples and 28/80 malignant samples. (B) Plots of PCSP 
cell burden in cohort 1 and (C) cohort 2 malignant tissues showed that a subset of Gleason 5 
patients had a particularly high burden in both cohorts. 
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Figure 1.  Scattered Syndecan-1 positive cells are found in the stroma of prostate carcinoma tissue. (A) 
Expression of Syndecan-1 in adjacent normal and prostate adenocarcinoma tissue. Syndecan-1 is expressed 
in the basal cells of adjacent normal tissue. In prostate carcinoma Syncecan-1 expression is lost or found to 
be broadly expressed in the epithelium. In addition, in a subset of prostate cancer cases Syndecan-1 
positive cells were found scattered in the stroma (shown in the insets and by arrows), but not in adjacent 
normal prostate tissue. We call these cells Prostate Cancer Syndecan-1 Positive (PCSP) cells and they could 
be found in the contexts of both epithelial Syndecan-1 alterations in tumors, including expression across all 
epithelial cells, and where Syndecan-1 expression is lost in the epithelium. (B) Examples of PCSP cells 
detected by anti-Syndecan-1 IHC. PCSP cells were located in the stroma and tend to appear near regions 
that appear to contain immune cells with small, round, hyperchromatic nuclei. Images are from 3 
Independent patient cohorts. Nuclei are counterstained with hematoxylin (blue) in IHC, or with DAPI (blue) 
in IF. IHC scale bars – 100um; IF scale bars – 50um. SDC1 – Syndecan-1.  
 
278x293mm (300 x 300 DPI)  
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Figure 2. Three distinct anti-Syndecan-1 antibodies show the expected patterns of Syndecan-1 expression in 
control prostate and tonsil tissue, and stain scattered stromal PCSP cells. (A) Staining of adjacent tissue 
sections of a representative adjacent normal prostate and tonsil positive controls with two different mouse 
monoclonal antibodies recognizing Syndecan-1. Both antibodies stained basal cells in adjacent normal 
prostate epithelium and epithelium in tonsil as expected. (B) Staining of adjacent tissue sections of 
representative adjacent normal prostate and tonsil positive controls with a mouse monoclonal and rabbit 
polyclonal antibodies that both recognize Syndecan-1. These antibodies also stained basal cells in adjacent 
normal prostate epithelium and epithelium in tonsil as expected. (C) Three anti-Syndecan-1 antibodies 
recognise similar stromally-located PCSP cells in both prostate tumors and in adjacent normal prostate 
tissue. Example cells are highlighted in the magnified insets and with the arrows. Nuclei are counterstained 
with hematoxylin (blue) for IHC. Scale bars – 100um with inserts at 3x zoom; SDC1 – Syndecan-1; mo – 
mouse; rb – rabbit.  
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Figure 3. Staining from two anti-Syndecan-1 antibodies overlap in individual  prostate epithelial cells and in 
the PCSP cells seen in the stroma of prostate tumors. Mouse monoclonal anti-Syndecan-1 antibody #1 and 
the rabbit anti-Syndecan-1 antibodies stained the same cell population following IF staining of prostate 
tissue. Overlap was seen in the basal cells of adjacent normal (Upper panels: See inserts) and in the PCSP 
cells found in the stroma of tumor tissues (Lower panels: See arrows and inserts). Nuclei were 
counterstained with DAPI (blue) in IF. Scale bars – 50um. SDC1 – Syndecan-1; mo – mouse; rb – rabbit.  
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Figure 4. PCSP cells do not express common markers of immune cell lineages. FFPE sections of prostate 
tumor tissue were stained for Syndecan-1 (green) and immune cell markers (red). Nuclei were 
counterstained with DAPI (blue). (A) PCSP cells (inset) do not express the hematopoietic lineage marker 
CD45, the B-cell marker CD19, the plasma cell marker CD27 or the lymphocyte and mesenchymal stem cell 
marker CD73. (B) Quantification of the percentage overlap of Syndecan-1+ cells with the marker stains. 
Counts of PCSP cells were pooled from a minimum of 3 different patient samples, with a minimum of 200 
cells counted in total per marker over at least 5 fields of view, with the exception of CD73 where 58 PCSP 
cells were counted. Scale bars – 50um. Insets: individual PCSP c lls displayed at 3x zoom. SDC1 – 
Syndecan-1.  
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Figure 5. PCSP cells do not express markers of epithelial and secretory prostate cells. FFPE sections of 
prostate tumor tissue were stained for Syndecan-1 (green) and epithelial markers (red). Nuclei were 
counterstained with DAPI (blue). (A) PCSP cells (inset) do not express the epithelial cell markers pan-
Cytokeratin or E-Cadherin. Similarly, the secretory epithelial marker PSA was not expressed in PCSP cells. 
(B) Quantification of the percentage overlap of PCSP cells with marker stains. Counts of PCSP cells were 
pooled from a minimum of 3 different patient samples. A minimum of 200 cells were counted in total per 
marker over at least 5 fields of view, with the exception of E-Cadherin where 176 cells were counted. Insets: 
individual PCSP cells displayed at 3x zoom. (C) Sequential sections of adjacent normal prostate and prostate 
tumors were stained for Syndecan-1 and the basal cell markers p63 and CK5, showing no colocalization in 
PCSP cells of tumor cases, despite the overlap seen in the basal epithelial cells of adjacent normal tissue. 
Insets and arrows show representative PCSP cells. Scale bars – 50um. SDC1 – Syndecan-1.  
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Figure 6. PCSP cells do not express common markers consistent with a mesenchymal, stromal, neural or 
endothelial cell identity. FFPE sections of prostate tumor tissue were stained for Syndecan-1 (green) and 
mesenchymal/stromal cell type markers (red), and nuclei were counterstained with DAPI (blue). (A) 
Mesenchymal cell type markers Vimentin, N-Cadherin, nerve marker S100 and endothelial cell marker CD31. 
(B) Quantification of the percentage overlap of PCSP cells with marker stains. Counts of PCSP cells were 
pooled from a minimum of 3 different patient samples. A minimum of 200 cells were counted in total per 
marker over at least 5 fields of view, with the exception of Vimentin, N-Cadherin and S100, where 69, 197 
and 29 cells were counted respectively. Insets: individual PCSP stromal cells displayed at 3x zoom. Scale 
bars – 50um. SDC1 – Syndecan-1.  
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Figure 7. PCSP cells are elongated and have prominent lamellipodia-like structures. (A) Pooled single cell 
measurement data of PCSP cells from both tissue microarray cohorts. A continuum between a more rounded 
cell morphology (circularity and aspect ratio close to 1) and a tail of cells assuming a more elongated cell 
shape with lower circularity and higher aspect ratio was observed. (B) Sequential slices through a z-stack of 
images of PCSP cells in a prostate tumor tissue section. PCSP cells had an elongated cell morphology, with 
polarized nuclei and lamellipodia-like protrusions. Optical sections are 1um apart. Blue: DAPI; Green: 
Syndecan-1. Scale bar: 10um. SDC1 – Syndecan-1.  
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Figure 8. Distribution of PCSP cells in normal, adjacent normal and prostate carcinoma. (A) Plots of PCSP cell 
burden in cohort 1. PCSP cells were detected in 0/8 normal samples, 4/8 adjacent normal (NAT) samples 
and 28/80 malignant samples. (B) Plots of PCSP cell burden in cohort 1 and (C) cohort 2 malignant tissues 
showed that a subset of Gleason 5 patients had a particularly high burden in both cohorts.  
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Supplementary Figure 1. Immunohistochemistry with anti-immune cell marker antibodies 
on positive control paraffin-embedded tissue sections. As expected, CD45, CD19, CD27 
showed cytoplasmic and membranous staining in lymphocyte populations in the tonsil and 
CD73 marked lymphocytes in the placenta. Nuclei were counterstained with haematoxylin 
(blue). IHC scale bars – 100um. 
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Cohort 1 
(PR1921) % 
Cohort 2 
(PR803b) % 
Number of Patients 80  71 
 
  
  Age:   
 Range 20-85  20-87 
Mean 67.85  67.6 
Median 69.5  70 
<50 2 2.5 3 4.2 
50-59 5 6.3 4 5.6 
60-69 33 41.3 27 38.0 
>=70 40 50.0 37 52.1 
  
  Clinical Stage:   
 I 6 7.5 2 2.8 
II 37 46.3 33 46.5 
III 14 17.5 10 14.1 
IV 22 27.5 26 36.6 
ND 1 1.3 0 0.0 
  
  Primary Gleason Grade:   
 3 8 10.0 19 26.8 
4 36 45.0 24 33.8 
5 30 37.5 24 33.8 
ND 6 7.5 4 5.6 
  
  Overall Gleason Grade:   
 <=Gleason 3+4 8 10.0 16 22.5 
>=Gleason 4+3 66 82.5 51 71.8 
ND 6 7.5 4 5.6 
  
  T Category:   
 T1 4 5.0 2 2.8 
T2 47 58.8 40 56.3 
T3 22 27.5 21 29.6 
T4 6 7.5 8 11.3 
ND 1 1.3 0 0.0 
  
  N Category:   
 N0 64 80.0 51 71.8 
N1 15 18.8 18 25.4 
N2  0.0 2 2.8 
ND 1 1.3 0 0.0 
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M Category   
M0 64 80.0 49 69.0 
M1 15 18.8 22 31.0 
ND 1 1.3 0 0.0 
  
SDC1 Epithelial Reactivity:   
Absent 66 82.5 57 80.3 
Present 14 17.5 13 18.3 
ND 0 0.0 1 1.4 
     
PCSP Cell Presence:     
Absent 52 65.0 56 78.9 
Present 28 35.0 15 21.1 
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Antibody 
Species of 
Origin 
Clonality 
[Clone Number] 
Working 
Dilution 
Supplier Catalogue No. 
Syndecan-1 
(SDC1) 
Mouse Monoclonal 
[B-A38] 
1:200 Novus 
Biologicals 
NB100-64980 
Syndecan-1 
(SDC1) 
Rabbit Polyclonal 1:50 Santa-
Cruz Biotechnology 
Sc-5632 
Syndecan-1 
(SDC1) 
Mouse Monoclonal 
[MI15] 
1:25 Dako N/A 
CD45 Rabbit Polyclonal 1:50 Santa-
Cruz Biotechnology 
Sc-25590 
CD19 Rabbit Monoclonal 
[EPR5906] 
1:250 Abcam Ab134114 
CD27 Rabbit Monoclonal 
[EPR8569] 
1:100 Abcam Ab131254 
CD73 Rabbit Polyclonal 1:25 Abcam Ab115289 
Pan-
Cytokeratin 
Mouse Monoclonal 
[C-11] 
1:100 Sigma-
Aldrich 
C2931 
E-Cadherin Mouse Monoclonal 
[4A2C7] 
1:25 Thermo 
Fisher Scientific 
33-4000 
Prostate-
Specific Antigen 
(PSA) 
Rabbit Polyclonal 1:50 Dako A0562 
p63 Mouse Monoclonal 
[BC4A4] 
1:50 Abcam Ab735 
Cytokeratin
-5 
Rabbit Polyclonal 1:1000 Abcam Ab24647 
Vimentin Mouse Monoclonal 
[V9] 
1:50 Santa-
Cruz Biotechnology 
Sc-620 
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N-Cadherin Rabbit Polyclonal 1:100 Abcam Ab18203 
S100 Rabbit Polyclonal 1:2000 Dako Z0311 
CD31 Mouse Monoclonal 
[JC70A] 
1:30 Dako M0823 
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 Cohort 1 (PR1921) Cohort 2 (PR803b) 
 Mean across 
samples 
Stdev across 
samples 
Mean across 
samples 
Stdev across 
samples 
Area 66.42 35.09 72.14 41.31 
Circularity 0.69 0.12 0.70 0.13 
Aspect 
Ratio 
1.88 0.62 1.83 0.68 
Roundness 0.58 0.16 0.60 0.17 
Solidity 0.88 0.06 0.88 0.07 
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